When will Zelsuvmi go generic?
What is the NCE-1 date for Zelsuvmi?
What are Zelsuvmi’s sales?
When was Zelsuvmi approved?
The 5-year NCE exclusivity for Zelsuvmi (berdazimer) runs until 5 January 2029, so generic entry is not expected before then. Actual launch timing also depends on any patents, other exclusivities, Paragraph IV litigation and FDA review.
The NCE-1 date for Zelsuvmi (berdazimer) is 5 January 2028, four years after approval. From that date, if patents are listed for it in the FDA Orange Book, generic companies can submit an ANDA with a Paragraph IV certification challenging them. The first filer may qualify for 180-day generic exclusivity.
Sales of Zelsuvmi (berdazimer) are projected to grow from about $6M in 2026 to about $40M by 2032. The innovator is LNHC Inc.
The FDA approved Zelsuvmi (berdazimer) on 5 January 2024. It is used to treat molluscum contagiosum. The innovator is LNHC Inc and it is available as a topical gel.